Previous 10 | Next 10 |
On the heels of its meeting with the FDA, Apellis Pharmaceuticals (NASDAQ: APLS ) announces that it expects to file a marketing application in H2 seeking approval of pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease in which the immune sys...
Akari Therapeutics Releases Positive Top Line Data Akari Therapeutics ( AKTX ) reported encouraging results from its Phase 2 study of Nomacopan. The study met its primary endpoint which was related to no drug-related adverse events. The drug candidate was granted Orphan Drug designation ...
NEW YORK and LONDON, May 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today ann...
Medigus (NASDAQ: MDGS ) +76% on first order for COVID-19 blood test . More news on: Medigus Ltd., Myomo, Inc., Akari Therapeutics, Plc, Stocks on the move, , Read more ...
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) is up 16% premarket on average volume in reaction to positive results from a Phase 2 clinical trial evaluating lead drug Coversin (nomacopan) in nine patients with bullous pemphigoid , a rare skin disorder characterized...
Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid and clinically significant reduction in Bullous Pemphigoid Disease Area Index (BPDAI) score Nomacopan has potential to repla...
Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date - Interim Phase II bullous pemphigoid (BP) data demonstrated a rapid and significant improvement in symptoms with a mean 63% decline in Bullous Pemphigoid Disease Area Index (BPDAI) score and...
NEW YORK and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today annou...
Investment Thesis Alexion Pharmaceuticals, Inc. ( ALXN ) is yet to recover from the last year's patent challenges to the leading revenue generator, Soliris. Over the past twelve months, the stock has lost more than a fifth while the Nasdaq Biotechnology Index has gained nearly a tenth. See...
Thinly traded nano cap Akari Therapeutics ( AKTX +5.9% ) is up on average volume in reaction to preclinical data on a long-acting version of lead drug nomacopan (PAS-nomacopan) that, it says, supports its use for back-of-the-eye diseases with less-frequent injections. More news on...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...